star boom china biotech market
larg cancer drug market china china becom one largest
oncolog market world-wide enjoy compound-annual-growth-rate past ten
year new cancer treatment three time number
respons patient china vs us estim peak sale
china reach bn includ combo beigen
among lead player potenti market share
beigen strong pipelinein us china beigen
strong pipelin two lead btk inhibitor
antibodi forecast launch china
us estim reach mn
mn china mn oversea peak sale reach
bn peak sale china bn oversea royalti bn
alreadi discount success rate beigen also invest
mn last year on-going clinic trial three late-
stage assetson largest invest chines biotech
btk inhibitor china food drug administr
cfda major catalyst beigen near term
apart present new data btk inhibitor annual
european haematolog associ eha confer june
late-stag data show better efficaci versu ibrutinib
posit driver current estim conserv compani may
also present phase data nda
initi outperform target price
potenti upsid forecast compani continu oper
net loss due larg invest small product sale
contribut beigen profit expect surg driven
product approv tp base discount cash
flow dcf model assum wacc perpetu growth rate
risk includ clinic trial failur delay launch product lower-
than-expect sale growth fx fluctuat
valuat metric
chang previou ep
insight invest idea
number share mn
price month
price rel chart measur perform
china close
spot exchang rate
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
charl martineau pm univers toronto focu chart tabl
figur china cancer therapi market
compound-annual-growth-rate
figur china larger cancer patient base
much smaller exist cancer drug sale vs us
figur forecast conserv
compar exist ibrutinib sale
figur forecast beigen global sale
consider clinic success probabl
region
incid respons
tumor region
royalti beigen success rate
total china sale success rate
figur timelin near- mid-term catalyst
abbrevi r/r relapsed/ refractori hl hodgkin lymphoma mcl mantl cell lymphoma american societi clinic oncolog uc urotheli carcinoma escc
charl martineau pm univers toronto one best biotech
compani china
upgrad demand
benefit lead
beigen
four candid
pipelin two
expect launch
beigen conduct
clinic trial six
combo therapi
see larg intern
star boom china biotech market
initi coverag beigen lead china firm focus develop
cancer therapi believ one best biotech compani two lead
productsbtk inhibitor contribut bn peak
sale assum indic approv beigen well posit
china oncolog drug market strong product pipelin experienc
manag team also build sale forc two new drug launch
expect transit fulli fledg biotech firm revenu
boom upgrad china cancer drug market
china becom one largest oncolog market world-wide enjoy
compound-annual-growth-rate past ten year estim continu compound-annual-growth-rate
next five year bn demand upgrad estim cutting-edg
therapi surg compound-annual-growth-rate driven grow overal market new
therapi replac out-of-d treatment acceler drug approv process
expand medic insur coverag see grow market scale upgrad
demand benefit lead innov compani beigen
bgne late-stag pipelin near-term catalyst
beigen four candid pipelin two blockbust drug expect
launch make assumpt drive forecast
summaris figur page assumpt includ number patient
price potenti market share beigen clinic trial success rate
littl conserv btk revenu estim beigen hasnt disclos
late-stag head-to-head comparison data approv btk estim drug
reach around mn peak sale mn china mn
oversea market discount clinic trial success rate compani
plan present updat data june eha believ better
efficaci data compar exist drug would posit driver stock price
see beigen strong player china expect take
market share bn peak sale key indic combo therapi
success approv also cooper celgen develop
commercialis oversea market count bn peak
sale beigen submit nda cfda present updat data
around time would import event stock price
combo therapi becom common due part superior efficaci
lower resist rate beigen conduct clinic trial six combo therapi
four product pipelin three alreadi commercialis product celgen
see larg intern combo therapi potenti estim combo therapi contribut
around beigen revenu long run count advanc
clinic trial zanubrutinib gazyva model mn sale
price potenti upsid
initi coverag beigen outperform rate target price
forecast compani continu see net loss due larg
 expens small product sale contribut target price
base multi-stag dcf model assum wacc perpetu growth
rate risk includ failur clinic trial potenti delay launch pipelin
product lower-than-expect sale commercialis exchang rate fluctuat
beigen commercial-stag biopharmaceut compani root
china dedic becom global leader
discoveri develop commercialis innov
molecularli target immuno-oncolog drug treatment
cancer
good sold
profit tax
free cash flow firm
net chang cash
blue sky valu us reflect faster-than-expect
approv beigen pipelin product
china global
grey sky valu reflect slower-than-expect
approv beigen pipelin product
china global
price rel chart measur perform china
close
spot exchang rate
tabl content
focu chart tabl
boom upgrad china cancer drug
bgne late-stag pipelin near-term catalyst
boom upgrad china cancer drug market
bgne late-stag pipelin near-term catalyst
price potenti upsid
season manag team support busi
sky/grey sky tp
holt view
detail sale forecast zanubrutinib tislelizumab
experienc manag research team
terminolog abbrevi
boom upgrad china cancer drug
china becom one world largest oncolog market larg age
popul moreov increas diseas awar enhanc
treatment resourc access increas dispos incom addit well-construct
public medic insur cover major popul
figur driver china oncolog market
china becom one
world largest
oncolog market
compound-annual-growth-rate past
china cancer incid rate increas sinc driven age
popul modern lifestyl higher diagnosi rate base nation cancer
statist china cancer centr new case increas mn
everi year pleas note statist alway lag three year thu
china cancer statist report publish earli repres data
mn new cancer patient china account global case
twice us number new cancer patient
figur cancer incid china
figur china cancer incid age
cancer statist china
cancer statist china
cancer case china exhibit concentr sever particular type lung
cancer breast cancer liver cancer oesophagu cancer
gastric cancer incid cancer togeth account signific
portion total incid around world
figur incid certain type cancer account signific part
total incid around world
rest world
china world total
although observ fast-grow china cancer market driven increas
incid rate still see china market greatli lag oncolog drug sale
compar us china around new cancer incid everi
year oncolog drug sale china account one-sixth us
increas cancer case higher treatment rate growth cancer drug sale
china outpac us accord data evaluatepharma third-parti
colorectal/gastr cancer china significantli higher us thu
china cancer treatment market estim grow even larger us market
long run see compound-annual-growth-rate china cancer market
number peopl
figur china cancer drug market compound-annual-growth-rate past decad
charl martineau pm univers toronto despit market enjoy compound-annual-growth-rate past ten year current spend
oncolog treatment much delay versu develop countri china
twice number cancer patient us oncolog drug sale account
less us market base im data
figur china doubl us
term number newli ad cancer case
figur yet greatli lag oncolog drug sale
grow lag oncolog market gaug top-sel drug
china versu us oncolog drug account four ten global best-sel
drug total bn global sale versu none ten domest
bestsel drug show oncolog drug market significantli unaddress
china incid diagnosi rate gradual go still plenti growth
potenti oncolog drug new cutting-edg therapi approv better
figur four global bestsel drug cancer treatment
compar none china
expect oncolog drug sale continu grow quickli probabl highest among
region support larger patient popul base increas
medic expenditur per capita chines citizen still see room medic expens
grow percentag china compar us
still exist exist treatment
although cancer drug seen rapid growth china past year see
gap cancer treatment us china summaris major
differ cancer treatment success measur five-year surviv
rate low surviv rate china result combin factor low
penetr rate routin medicin check late-stag diagnosi low afford lack
charl martineau pm univers toronto advanc cancer drug cancer treatment lag china versu us tradit
chines medicin tcm drug still play import role treat
figur five-year surviv rate differ type cancer us china
melanoma skin
even though china regul work acceler new drug approv
still mani advanc drug therapi yet approv china patient suffer
critic diseas especi cancer cardiovascular problem start
seek advanc treatment regul market
figur top destin cross-bord medic
us japan two popular destin base data sant lucia
consult one earliest cross-bord medic consult agenc averag
asp treatment howev cancer treatment improv recent
year china still see gap exist surviv rate believ
gradual narrow advanc cancer drug approv china
importantli becom afford patient
medic reform china deepen china regul made great effort bring
drug domest market acceler drug approv process
includ acceler drug approv lower cutting-edg drug cost nation drug
price negoti remov oncolog drug tariff motiv domest
acceler track approv advanc cancer drug
februari cfda issu polici set prioriti review list order
acceler ind investig new drug nda approv process drug
great clinic trial valu superior efficaci end applic
review drug success pass nda launch fast-track
pathway one-fifth oncolog drug
cfda continu issu new batch prioriti review drug list batch
issu far expect oncolog drug good qualiti potenti great
clinic valu get approv launch china would bring upgrad
therapi domest patient latest batch prioriti review list three domest
antibodi innov junshi hengrui includ
figur cancer drug approv prioriti review list
bortezomib inject
pemetrex disodium inject malign pleural mesothelioma
azacitidin inject
reason get includ
file nda eu
new drug great clinic valu
new drug great clinic valu
new drug great clinic valu
new drug great clinic valu
new drug great clinic valu
new drug great clinic valu
new drug great clinic valu
insur reimburs process acceler cancer drug
growth upgrad cancer drug also support better medic
insur coverag fifteen cancer drug
new nation
reimburs drug list nrdl negoti account almost half
drug includ manufactur larg cut cutting-edg therapi price
averag elig includ drug public medic insur coverag
includ drug superior efficaci expens patient
past cut drug price includ nrdl larg
improv ir penetr rate improv treatment therapi benefit patient
believ insur negoti process oncolog drug also acceler
futur help larg drive cancer drug penetr rate
figur oncolog drug includ new nrdl negoti
bortezomib inject
trastuzumab inject
charl martineau pm univers toronto beigen btk
inhibitor
near-term pipelin
bgne late-stag pipelin near-term
beigen one best biotech compani china view all-star
manag team strong product pipelin figur four develop
dimer inhibitor parp inhibitor one monoclon antibodi
immun checkpoint inhibitor tislelizumab compani also
conduct clinic trial six combo therapi zanubrutinib gazyva alreadi
carri phase ii trial fl larg lymphoma categori
estim sale compani two major product
peak bn bn respect assum
indic pipelin approv progress differ product major
launch time btk differ indic list figur
figur compani ten therapi clinic trial
syndrom aml acut myeloid leukemia uc urotheli carcinoma cmmol chronic myelomonocyt leukemia first second third line r/r relapsed/refractori nd newli
diagnos indic requir non-pivot phase clinic trial prior begin phase clinic trial confirmatori clinic trial post approv requir
acceler approv revlimid approv combin therapi dexamethason
target nda submiss btk inhibitor cfda
potenti approv would major catalyst compani near term
besid compani present new data btk inhibitor annual
european hematolog associ eha confer june may also
present phase data nda summaris forecast
indic launch time figur
charl martineau pm univers toronto figur timelin near- mid-term catalyst
abbrevi r/r relapsed/ refractori hl hodgkin lymphoma mcl mantl cell lymphoma american societi clinic oncolog uc urotheli carcinoma escc
drive revenu forecast ad everi
indic sale contribut rel year drug sale model assum
variou diseas incid diagnos respons rel drug penetr rate
market share averag spend per patient success rate enter
commercialis stage summaris assumpt figur success
rate project differ clinic stage use us histor data refer see
appendix compar higher rate china
figur driver assumpt model
base assumpt figur deriv sale forecast figur
estim reach mn mn china mn
oversea peak sale reach bn peak sale china
bn oversea loyalti bn compani also invest
mn last year one largest among chines biotech
on-going clinic trial three late-stag asset
charl martineau pm univers toronto estim quit conserv even though pre-clin data
shown advantag ibrutinib compani still disclos late stage
rest world launch year
rest world royalti beigen
rest world royalti beigen
rest world launch year
program death program death-ligand
emerg import cancer biomark target immunotherapi
proven improv safeti efficaci treat sever cancer fda
approv keytruda treat solid tumour specif genet featur make
keytruda first therapi approv diseas specif genet featur
estim compani gener mn peak sale
includ china sale loyalti fee global sale peak sale estim would
lower mn factor clinic trial success rate
global market continu grow intens competit
global sale surg first therapi keytruda
approv septemb opdivo bm three month
keytruda opdivo total record bn sale
second/third full year launch tecentriq roch deliv
mn sale launch octob sale ramp
mn imfinzi az approv fifth
therapi keytruda approv first drug solid tumour
charl martineau pm univers toronto figur product approv world-wide
base data research agenc research market drug
approxim activ clinic trial pipelin trial
new drug combin therapi driven improv safeti efficaci
expand indic combin therapi estim global market
experi sale compound-annual-growth-rate reach bn growth
would driven solid tumour indic approv combin therapi
quit conserv tislelizumab oversea market assum
market share indic late-stag phase ii phase clinic trial
given intens competit exist drug keytruda opdivo
approv larg pharmaceut compani
splendid market pd-/ china
expect china one largest market long run
largest respons patient consid respons incid rate
china largest patient base respons tumour around mn
incid per year compar mn us mn countri
therapi china approv novemb
bm hand opdivo applic approv cfda first among pd-
drug msd also appli nda februari see opdivo like
first therapi approv china among domest compani
innov withdrew applic march re-appli april hengrui
pharma appli nda april bm innov junshi
hengrui includ prioriti review list acceler
market size china
estim peak sale china around bn
beigen around market share china around mn
respons tumour patient threefold us howev price
domest product would lower global price mnc meanwhil
patient afford would wors china us due absenc
commerci insur consid factor estim market
china around us market peak sale due lower treatment rate
price
respons rate differ cancer vari base
studi cancer publish new england journal medicin compris
cutan squamous-cel merkel-cel melanoma non-colorect mmrd cancer
respons rate asian patient slightli differ studi
figur correl tumour mutat burden object respons rate
therapi tumour type
compani data new england journal medicin
consid respons incid rate china largest patient base top-
respons tumour around mn incid per year compar mn
us mn among type nsclc gastric cancer oesophag
charl martineau pm univers toronto largest sale among cancer china larg
respons patient base expect largest driver market
figur incid respons tumour
figur china market major cancer
china data us data data japan data
current around clinic trial conduct indic
china estim total enrol patient could reach
therapi meanwhil hospit authoris carri clinic trial
mean doctor patient well-educ treatment
also help compani penetr therapi approv reach
decent sale scale immedi commercialis
mnc ahead domest player nivolumab
ten phase clinic trial pembrolizumba four howev
prefer domest player market due price advantag establish
market platform averag spend opidivo us per month
around per patient per year combin therapi around
without commerci insur common china chines famili could
afford treatment mnc includ china price
basket unlik price larg discount compar
figur monthli averag spend us
note drug price base milligram medicin use vari weight individu patient bavencio price wholesal
acquisit cost averag patient estim domest compani price around mnc price
mani domest product clinic trial stage hengrui junshi
innov indic clinic trial phase innov
alreadi hand nda inject target patient hodgkin
lymphoma hl first domest compani appli nda april
hengrui also hand nda
figur china applic clinic trial comparison tabl
oesophag cancer ec enktl recurr refractori hodgkin lymphoma
nsclc advanc oesophag cancer advanc liver cancer combo apatinib
nsclc advanc liver cancer advanc nsclc recurr refractori hodgkin lymphoma enktl
recurr metastat nasopharyng carcinoma advanc solid tumour
solid tumour tislelizumab pamiparib solid tumour hematolog tumour
see advantag mnc china longer track record
wider varieti indic late-stag clinic trial potenti get approv
advantag domest player strong market team afford
price believ beigen posit best china market
advantag mnc domest compani
believ beigen price middl mnc domest
compani co-oper celgen develop global market
show world-class capac drug qualiti strong efficaci less
compani could leverag celgen well-establish oncolog team
compani carri clinic trial three indic phase two trial
phase ii solid tumour indic phase
among futur player china includ mnc domest
compani believ hengrui beigen largest winner hengrui
tislelizumab clinic trial approv
see first indic approv tislelizumab r/r hodgkin lymphoma hl
china compani carri phase trial nsclc global china
carcinoma escc global china phase ii trial r/r hodgkin lymphoma hl
china urotheli carcinoma ucc china also combo therapi
clinic trial includ parp btk indic beigen
carri clinic trial first-lin second-lin treatment grant
compani guid hl clinic trial phase ii first indic
approv china compani target submit nda
estim approv take around month hl around new incid
china everi year much smaller nsclc explain clinic
charl martineau pm univers toronto trial phase howev see larg off-label sale nsclc cancer
hl indic approv
figur clinic trial
indic requir non-pivot phase clinic trial prior begin pivot phase clinic trial
confirmatori clinic trial post approv requir acceler approv
tislelizumab clinic data suggest toler efficaci differenti
possibl beigen present phase data confer american
societi clinic oncolog chines societi clinic oncolog
compani may present late-stag data near nda
preliminari result patient advanc ovarian cancer compani
present european societi medic oncolog confer patient
evalu defin measur base-lin tumour assess least one
evalu post-bas line tumour respons assess progress die prior
initi tumour assess
patient achiev confirm progress pr patient achiev best overal
respons stabl diseas sd
diseas control rate dcr pr sd
median treatment durat patient oc day
charl martineau pm univers toronto toler safeti
figur safeti toler data select clinic trial
gc escc
treatment-rel advers event trae occur
trae occur
patient gc ec
patient
treatment tislelizumab gener well
toler pre-treat patient uc
one event
treatment-rel tr occur
patient fatigu
hyperglycemia type diabet
mellitu consid
relat treatment grade
one patient discontinu treatment due
infusion-rel reaction consid relat
one advers event muscl weak
consid relat treatment
report patient uc consist
overal safeti profil observ studi
gener low moder sever
across cohort fatigu decreas appetit abdomin
pain nausea commonli report trae
major trae grade sever
common event
one patient cohort report trae grade
-seriou advers event consid relat treatment
occur two patient gc diarrhoea pyrexia
total eight patient cohort gc
ec trae fatal event
advers event report cohort consist
overal safeti profil observ studi
gener low sever manag revers
rash pruritu
treatment due treatment
emerg ae one
grade ae consid relat
treatment investig
advers event report
cohort consist
overal safeti profil observ
studi gener low
sever manag revers
believ beigen posit one best molecul among
player china includ mnc larg domest player believ
tislelizumab price middl charg mnc domest
compani compani cooper celgen develop global
market show world-class capac drug qualiti strong efficaci less
toxic leverag celgen well-establish oncolog team penetr
sale compani carri clinic trial three indic phase
two trial phase ii solid tumour indic phase varieti
indic grant tislelizumab larg potenti market size
estim china peak sale bn bn factor success rate
see first indic approv china hl even though compani
academ promot off-label usag believ doctor use
indic off-label driven strong demand therapi nsclc
solid tumour mani patient china buy grey market
parallel import hong kong pharmaci patient seek
cross-bord treatment us hong kong due absenc china
compani alreadi start phase clinic trial three indic show
certain efficaci toxic toler around clinic trial carri
ten player china indic multi hospit well-educ
doctor use therapi off-label usag drug strictli restrict
china us
expect approv timelin bm msd hengrui innov beigen
quit close one besid first approv indic differ
thu first-to-market posit import innov drug
market china view
long term estim nsclc indic contribut sale
follow hl escc ucc nsclc cancer highest incid
china around new patient per year howev nsclc quit
competit indic late-stag clinic trial china
still contribut largest share sale tislelizumab given larg market size
hl much smaller market compar nsclc term incid rate
hand hl highest respons rate among cancer around
meanwhil beigen first runner indic thu estim indic
gener second-largest share sale
figur incid indic late-stag trial beigen
cancer late stage trial
incid rate china median life durat patient number
figur tislelizumab sale china indic
boehring ingelheim bi charg manufactur china
tislelizumab approv beigen manufactur site construct
investig finish beigen co-oper bi clinic trial product
manufactur sinc bi one world largest biolog contract manufactur
organis long solid track record manufactur biolog
made world-wide
meanwhil beigen construct manufactur site guangzhou
local govern total bn invest site long term
guangzhou plant main manufactur site tislelizumab see capac
constraint tislelizumab sale
beigen enter collabor celgen develop commercialis
tislelizumab global market exclud china juli receiv licens
fee up-front equiti stake receiv mileston fee well royalti futur
sale moreov beigen acquir celgen commerci oper china
alreadi three commercialis oncolog product abraxan revlimid
deal show compani standard qualiti drug
develop meet global first-class standard also save compani effort time
build oncolog platform
figur deal detail beigen celgen
royalti futur sale
beigen receiv up-front licens fee total mn
celgen acquir equiti stake beigen purchas mn share repres around
beigen share
beigen elig receiv mn develop regulatori sale mileston
tie certain sale sale reach certain scale
beigen acquir celgen commerci oper china gain exclus licenc
commercialis celgen approv therapi chinaabraxan revlimid vidaza
develop commercialis solid tumour cancer us europ japan rest
world outsid asia
base larg mileston fee celgen will pay tislelizumab
mn total futur sale royalti fee beigen receiv estim
global ex-china sale reach least bn bn factor
quit conserv tislelizumab oversea market assum around
market share indic late stage phase ii phase clinic
trial given intens competit exist drug keytruda opdivo
approv larg pharmaceut compani
royalti beigen success rate
total china sale success rate
treat varieti
potent highli select small molecul btk inhibitor bruton tyrosin
lymphoma mcl follicular lymphoma fl etc btk inhibitor pathway
control function cell antigen receptor bcr busi end
matur b-cell compani perform clinic trial lymphoma includ wm
cll/sll r/r diffus larg b-cell lymphoma etc forecast mcl china
first indic approv zanubrutinib follow cll china wm
ibrutinib johnson johnson first approv btk inhibitor
reach bn sale fourth full year commercialis
guid bn peak sale global see great potenti zanubrutinib sale
approv clinic privileg ibrutinib still conserv revenu
forecast compani still disclos late stage head-to-head comparison
data also johnson johnson stronger sale team global
surg btk ibrutinib global sale approv
imbruvica ibrutinib johnson johnson approv btk
inhibitor fda ema octob fda approv
calquenc astrazeneca btk inhibitor use treat mcl head-to-head
comparison data two drug
ibrutinib first approv fda mcl treatment later approv
treatment cll wm sll margin zone lymphoma mzl chronic graft
versu host diseas europ also approv ema cll mcl
wa august approv cfda use second-lin adult cll/sll
treatment china
approv imbruvica ibrutinib mantl cell lymphoma
approv imbruvica ibrutinib treat chronic lymphocyt leukemia
expand approv use imbruvica ibrutinib chronic lymphocyt leukemia
expand approv use imbruvica ibrutinib waldenstrm macroglobulinemia
approv imbruvica ibrutinib first-lin treatment chronic lymphocyt leukemia
expand imbruvica ibrutinib label includ overal surviv data previous untreat chronic lymphocyt
leukemia cll new indic small lymphocyt lymphoma sll patient
approv imbruvica ibrutinib first treatment specif indic relapsed/refractori margin zone
approv imbruvica ibrutinib chronic graft versu host diseas
fda approv novemb us fda approv ibrutinib first btk
inhibitor second-lin mcl treatment third drug mcl velcad
revlimid approv base studi mantl cell lymphoma patient whose
diseas come back longer respond treatment patient
studi respond ibrutinib mean lymphoma shrank respons
last averag month patient complet respons mean
sign cancer disappear guid fda
varieti indic approv includ major lymphoma cancer name
ibrutinib global sale surg reach bn contribut
johnson johnson project ibrutinib annual revenu reach
bn see peak sale bn ramp growth ibrutinib
shown clinic efficaci strong need btk inhibitor treat lymphoma
applic expand non-lymphoma
figur ibrutinib sale ramp-up quickli launch
clinic trial result zanubrutinib
compani perform clinic trial lymphoma includ wm cll/sll r/r
diffus larg b-cell lymphoma etc clinic trial includ global china trial
global trial wm run ahead other compani carri head-
to-head phase clinic trial wm versu ibrutinib plan initi head-to-head
phase trial cll versu ibrutinib
figur clinic trial zanubrutinib combo therapi
indic requir non-pivot phase clinic trial prior begin pivot phase clinic trial
confirmatori clinic trial post approv requir acceler approv br bendamustin rituximab
charl martineau pm univers toronto figur broad clinic develop plan zanubrutinib
indic zanubrutinib clinic trial quit similar ibrutinib make
zanubrutinib direct competitor ibrutinib may enjoy ibrutinib patient base
doctor well-coach prescript habit use btk inhibitor zanubrutinib show clinic
privileg ibrutinib head-to-head studi
clinic privileg ibrutinib
base pre-clin clinic data zanubrutinib potenti differenti
ibrutinib better safeti toler sustain inhibit diseas
origin tissu better oral bioavail better combin adcc-depend
data phase i/ii trial shown zanubrutinib privileg compar ibrutinib
acalabrutinib cmax pharmacolog area curv auc zanubrutinib
qd appear similar ibrutinib free drug
exposur zanubrutinib qd appear compar ibrutinib
indic advanced-stag clinic trial
believ mcl china first indic approv zanubrutinib
compani plan hand nda cfda like approv
view list indic incid r/r diffus larg b-
cell indic largest patient base china cll/sll indic
largest market potenti oversea
figur timelin indic late stage clinic trial
around new case china everi year account around non-hodgkin
lymphoma nhl nhl account lymphoma china lymphoma incid
rate china around per year
around new case china everi year incid rate popul
around new case china everi year incid rate popul
around new case everi year incid rate averag higher
around new case china everi year account nhl
around new case everi year median life durat ten year
around new case everi year nhl
commercialis china oversea
diseas zanubrutinib target orphan diseas
lymphoma cll/sll common white peopl asian
hand competit btk therapi also intens oversea market
compani aggress clinic trial strategi world-wide see zanubrutinib
similar sale contribut oversea market china
compani could leverag celgen well-establish oncolog platform sell
zanubrutinib china us regul market compani prefer
build sale team penetr zanubrutinib decid whether build
team cooper compani zanubrutinib could show final clinic
privileg ibrutinib could leverag larg patient base doctor prescript
habit coach johnson johnson prescrib btk inhibitor view
drug sale would boost quickli commercialis hand sinc
compani experi penetr drug oversea especi regul
market sell zanubrutinib could larg challeng
compani guid zanubrutinib price strategi world-wide china
ibrutinib sell per patient per year us/china
assum zanubrutinib price ibrutinib oversea market
ibrutinib china estim zanubrutinib sale peak
around mn mn consid success rate
mn expect china mn oversea estim
quit conserv given late-stag head-to-head studi data
present compani well-establish sale team world-wide
total china sale success rate
total oversea sale success rate
small-molecul raf inhibitor beigen develop
monotherapi combin therapi treatment cancer
aberr map-kinas mapk pathway includ braf mutat
mechan mapk pathway
mapk pathway chain protein convey signal receptor
surfac cell dna nucleu pathway made protein ra
three protein kinas raf mek erk act on/off switch regul
activ pathway sequenc ras-raf-mek-erk control gene
express determin cell fate aberr activ pathway
frequent found cancer cell mani cancer defect mapk pathway lead
uncontrol tumour growth
two key compon mapk pathway raf ra two
frequent mutat gene human cancer braf one three kinas belong
raf kinas famili frequent mutat one case
mutat braf ra result activ mapk pathway caus tumour
develop growth frequent braf mutat braf
figur mechan inhibit braf mapk pathway
compani data adapt wan et al credit suiss research
previous found develop braf inhibitor inhibit braf
monom contrast believ inhibit braf monom
raf dimer braf inhibitor-sensit resist melanoma cell model thu
superior efficaci make possibl address drug resist
issu braf mutat tumour also expand util ras-mut
potenti market opportun
sever approv raf inhibitor market includ roch zalboraf
vemurafenib novartiss tafinlar dabrafenib treat late-stag braf
mutant melanoma combin dabrafenib gsk trametinib mekinist
mek inhibitor approv patient braf mutation-posit metastat
applic braf mutat cancer ra mutat cancer
contrari first-gener fda-approv braf inhibitor limit efficaci
braf mutat pancreat ovarian endometri sever cancer
activ ra mutat includ kra nra
figur address unmet medic need kras/nra braf mutat
respons gener braf inhibitor
respons gener braf inhibitor
current beigen conduct phase ii clinic trial china world-wide
treatment b-raf- kras/nras-mut solid tumour expect beigen
advanc phase trial superior efficaci exist raf
inhibitor wider potenti patient base expect drug
launch china region
inhibitor beigen current develop
treatment homologous-recombination-defici cancer caus
abnorm dna repair mechan sensit parp inhibitor
mechan parp inhibitor dna repar
protein involv dna replic transcript regul
function dna damag sensor repair inhibit parp prevent
repair dna
charl martineau pm univers toronto figur mechan parp inhibitor prevent cancer dna repar
normal cell rel toler parp inhibitor thu dna repar
affect inhibitor howev cancer cell mutat brca gene
highli sensit parp inhibit thu inhibitor could use monotherapi
brca-mut cancer anoth potenti therapeut util parp inhibitor
use combin dna-alkyl agent treat variou cancer
potenti market opportun
one current approv product parp inhibit astrazeneca lynparza
olaparib treat germlin brca gbrca ovarian cancer current approv parp
inhibitor shown signific toxic lower respons rate brca mutat
cancer patient shown favour select
biochem assay improv specif cell line prolifer screen compar
parp inhibitor also shown abil penetr blood-brain
barrier studi mice
current beigen conduct phase ii pivot clinic trial global third-lin
gbrca mutat ovarian cancer conduct phase ii clinic trial china
solid tumour expect drug get approv china launch global
deal celgen compani acquir celgen commerci
oper china exclus licenc three commercialis product abraxan
revlimid vidaza three product total gener mn sale
consolid sinc septemb deal close see commercialis
product sale help gener cash flow compani importantli take
celgen china oper includ sale team help beigen penetr
product launch howev three product face challeng domest
compani estim sale compound-annual-growth-rate next three year
cspc approv earli
approv
product approv
expect pass
ndrl
negoti
abraxan approv indic breast cancer gener around mn
sale china abraxan follow advantag permit higher dose
paclitaxel administ compar toxic increas intratumour
paclitaxel concentr elimin solvent-rel sever easier
dose method compar taxol
howev market abraxan becom crowd cspc gener
approv earli hengrui gener like approv seven
compani also carri clinic trial includ larg pharma name
qilu pharma hisun pharma
see larg domest compani larg challeng sale abraxan
expect gradual lose market share meanwhil market expand quickli
domest compani carri aggress academ promot chang
abraxan contribut mn
revlimid approv treat patient mm china one
blockbust drug celgen global sale reach bn
indic includ mcl mm md sale rel weak china due
expens asp includ ndrl price cut around
believ price cut ndrl eros definit
boost revlimid sale volum surg offset price cut
beij pharma revlimid gener approv late commercialis earli
sino biopharm also conduct late-stag clinic trial gener revlimid
see beij sl pharma strong competitor lenalidomid without
establish brand oncolog sale team remlimid abl secur
domin posit year sino biopharm expect strong competitor
lenalidomid gener approv estim happen
estim revlimid contribut mn
vidaza approv china earli beign took celgen china
oper three indic md aml cmml approv clinic data
show could larg improv md patient median overal surviv month
compar tradit treatment month estim vidaza contribut
mn
although target cancer treatment suppress tumour progress induc
regress achiev high respons rate past complex immun cell
progress tumour make target therapi unlik address major
mechan imped anti-tumour immun patient
medic research proven combin therapi treatment modal
combin two therapeut agent cornerston cancer therapi oncolog
treatment often effect emerg resist consist
beigen develop i-o combin therapi i-o agent
tislelizumab three target therapeut current clinic studi
raf mutat dimer inhibitor
compani platform enabl advanc four candid clinic
like becom compani wholli clinical-stag btk inhibitor
inhibitor one compani discov advanc
clinic stage parp inhibitor inhibitor braf inhibitor inhibitor
use combin therapi besid compani three commercialis oncolog
drug celgen believ compani cancer biolog platform critic
develop ration combin would enabl becom leader next-
figur mechan combin therapi
within i-o platform combin therapi serv
cornerston core asset combin base pre-clin data
see rational exist combin beigen drug candid bgb-
tabl summaris clinic trial beigen conduct combin
therapi pipelin candid
charl martineau pm univers toronto figur combo therapi late-stag clinic trial beigen work
combin antibodi global pivot phase ii
beigen launch world-wide clinic trial combin therapi
combin obinutuzumab gazyva second-gener antibodi
mantl cell lymphoma tumour model treat r/r follicular lymphoma
combin obinutuzumab significantli efficaci
decemb beigen present updat preliminari clinic data
trial annual meet atlanta us data cut-off
septemb patient cll/sll patient fl enrol
trial preliminari phase data demonstr combin gener
well-toler highli activ patient fl tn r/r cll/sll
combin global phase ib
beigen launch combin studi base
encourag synergist effect observ preclin model primari diffus
larg b-cell lymphoma tumour model enhanc anti-tumour activ
observ especi
open-label multi-centr phase trial conduct australia current
dose-escal phase follow dose-expans phase initi dose-
escal data suggest combin
gener well-toler exhibit anti-tumour activ
patient b-cell
combin global phase ib
beigen launch combin studi parp inhibitor
patient advanc solid tumour compani present data phase
clinic trial januari asco-sitc clinic immuno-oncolog symposium
suggest combin therapi gener
well-toler show anti-tumour activ multipl solid tumour type
trial current plan evalu combin activ expans
patient ovarian
gastric/gastro-oesophag junction urotheli pancreat cancer
forecast combo therapi
combin total revenu
price potenti
compani list us februari stock price surg
sevenfold far histor valuat driver mainli includ
collabor larg mnc unbind import posit clinic data
follow-up public offer
preliminari phase data
chines patient
strateg collabor
celgen develop
million public
phase data
zanubrutinib combin
preliminari phase data multipl
compani data bloomberg professionaltm servic
beigen revenu consist sale in-house-develop product
current still pipelin develop stage mileston revenu form celgen
potenti cooper develop proprietari candid revenu
commercialis celgen product china
forecast beigen gener mn sale base
follow assumpt core pipelin candid includ
get approv within schedul global china
beigen receiv mileston fee celgen develop
cooper celgen continu sale celgen three commercialis
product china contribut mn sale
target price upsid base discount cash flow method
weight averag cost capit perpetu growth rate
alway use perpetu growth rate biotech name consid great
market potenti target therapi growth rate approach high-end
beigen valuat
includ success regulatori approv beigen pipelin
candid cooper celgen pharma name major
downsid risk list appendix uncertainti pipelin develop
regulatori approv beigen abil commercialis
anoth import factor support biotech compani whether compani
enough cash hand support drug januari compani announc
close follow-on public offer proce around mn ad
around mn deduct underwrit discount commiss year-end
cash compani round bn cash almost loan see
cash enough support compani except exist cash
balanc compani oper cash celgen product mileston fee
support product launch
-mileston payment celgen transact
rest world launch year
rest world royalti beigen
rest world royalti beigen
rest world launch year
season manag team support busi
valuat well-support beigen season manag team view
well-structur manag team key push clinic trial forward
commercialis biotech compani like beigen
compani led mr john oyler togeth well-establish manag
team strong industri experi peopl team serv
pharma compani scienc institut variou function in-depth
understand biotechnolog market well oper pharma compani
see detail manag team appendix
apart execut manag team also team talent scientist
great knowhow experi lead function beigen
senior team member phd relat field well-known univers led
project pharma compani earlier
appreci manag abil leverag industri experi develop
beigen busi believ manag capabl make plan progress
drug develop commercialis
also refer discount p/ justifi target price sinc
compani sale expect start surg onward new drug new
indic approv see sale better represent compani
stabl matur oper use sale estim discount wacc
come sale estim
comparison tabl includ biopharmaceut compani list
us similar market cap beigen base methodolog tp
charl martineau pm univers toronto repres p/ similar industri averag among
biopharma compani tp well-justifi p/ valuat method
sky/grey sky tp
compani beigen whose revenu mainli driven pipelin
product usual face certain risk success deliv progress given
uncertainti involv expect target price impact compani
success failur
beigen might get pipelin candid approv china global superior
clinic trial result well-conduct commun cfda/fda could
also end unsatisfactori clinic result delay drug launch china global
sens /grey tp deriv assumpt time
approv beigen major pipelin drug tp factor
faster-than-expect approv beigen pipelin product
china global grey tp factor slower-
than-expect approv pipelin product china global
unabl deliv plan progress pipelin develop
see beigen biggest risk inabl deliv schedul pipelin
develop progress factor could lead potenti failur pipelin
develop includ failur discov identifi drug candid
clinic develop failur delay patient enrol beigen clinic trial
uncertainti obtain regulatori approv pipelin candid
uncertainti launch product within schedul
beigen major revenu expect come commercialis drug
candid includ see risk
potenti failur launch product within schedul commercialis
risk includ obtain market accept drug candid
achiev adequ level accept compani may gener signific
product sale revenu may becom profit build sale team
compani current sale market commerci product distribut capabl
experi market drug thu build in-hous sale team
becom challeng term talent brand name peer competit
compani may face competit peer respect current drug candid
particular expect challeng antibodi segment
domest global market
uncertainti exchang rate fluctuat
compani incur portion expens potenti revenu currenc
usd rmb aud result compani expos foreign
currenc exchang risk oper cash flow suscept fluctuat
compani current engag hedg transact protect
uncertainti futur exchang rate foreign currenc usd
risk commercialis
compani may face difficulti commercialis product even success
launch target countri
holt view beigen
holt methodolog use proprietari perform measur known
return invest cfroi approxim econom return
estim averag real intern rate return earn firm portfolio
project constitut oper asset firm cfroi directli compar
real cost capit investor real discount rate see firm creat
econom wealth remov account inflat distort cfroi allow
global compar across sector region time comprehens metric
tradit roe
charl martineau pm univers toronto figur sale growth holt
figur margin holt
figur asset turn holt
figur beigen expect gener
appli key credit suiss analyst estim holt framework current
result valuat valuat initi use ten year key analyst
estim drive cfroi forecast proprietari algorithm determin rate
fade toward long-run averag cfroi valuat cfroi profil
support outperform
figur dcf valuat deriv tp
capital-expenditure rate chang revenu
chang work capit
npv cash-flow
npv perpetu
number share
debt
pre-tax debt
after-tax debt
equiti
risk-fre rate return
equiti
weight averag capit
sale
research develop
gener administr
amort intang asset
net loss attribut non-control interest
net incom loss attribut sharehold
non- adjust
research develop
gener administr
non-gaap net incom loss attribut sharehold
st invest
cash equival
properti equip net
advanc custom
accru expens payabl
accumul comprehens incom
total liabil stockhold equiti
flow oper
adjust reconcil net loss net cash use oper
chang oper asset liabil
prepaid expens current asset
advanc custom
accru expens payabl
net cash provid use oper activ
purchas properti plant equip
purchas available-for-sal secur
proce dispos available-for-sal secur
net cash provid use invest activ
proce share exercis share option
capit contribut non-controlling interest
proce sharehold loan
net cash provid use financ activ
effect exchang rate chang cash cash equival
net decreas increas cash cash equival
cash equival begin period
cash equival end period
note januari compani announc close follow-on public offer proce around mn compani data credit suiss estim
flow analysi januari beigen announc close follow-on public offer proce around mn ad around
mn deduct underwrit discount commiss year-end cash compani round bn cash almost loan
see cash enough support compani addit exist cash balanc compani oper cash celgen
product mileston fee support product launch
detail sale forecast zanubrutinib tislelizumab
figur zanubrutinib global sale forecast indic
beigen market share patient
zanubrutinib patient
oversea sale factor success rate us mn
beigen market share patient
zanubrutinib patient
oversea sale factor success rate us mn
beigen market share patient
zanubrutinib patient
oversea sale factor success rate us mn
total oversea sale factor success rate us mn
charl martineau pm univers toronto figur zanubrutinib china sale forecast indic
beigen market share patient
zanubrutinib patient
china sale factor success rate us mn
beigen market share patient
zanubrutinib patient
china sale factor success rate us mn
beigen market share patient
zanubrutinib patient
china sale factor success rate us mn
beigen market share patient
zanubrutinib patient
china sale factor success rate us mn
total china sale within label factor success rate us mn
total china sale factor success rate us mn
figur tislelizumab market china
beigen market share patient
china sale factor success rate
beigen market share patient
china sale factor success rate
beigen market share patient
china sale factor success rate
beigen market share patient
china sale factor success rate
beigen market share patient
china sale factor success rate
off-label sale sale
total china sale factor success rate us mn
mnc market share patient
beigen market share patient
oversea sale factor success rate
mnc market share patient
beigen market share patient
oversea sale factor success rate
mnc market share patient
beigen market share patient
oversea sale factor success rate
total oversea sale factor success rate us mn
royalti beigen us mn
drug busi never without risk report industri lobbi group
analys drug develop programm show
probabl success overal drug data includ
failur rate early-stag drug discoveri also worth note drug larger
market cardiovascular oncolog drug lowest likelihood
approv rate much lower orphan drug two area especi oncolog therapi
focu china drug
biolog much higher success rate averag drug china without
approv cutting-edg therapi compar us without strict
regul standard accept approv best-in-class drug requir
approv rate higher btk inhibitor ibrutinib drug approv
low patient afford current therapi approv china
data
test
phase
phase ii
phase
nda/bla
phase
figur likelihood approv phase among differ diseas
indic differ clinic trial stage beigen drug appli differ
success rate exampl zanubrutinib r/r mcl enter clinic trial phase
china multipli sale forecast incorpor sale
forecast model factor possibl clinic trial success pleas refer appendix
success rate assumpt indic adjust model refer
rel success rate drug progress advanc clinic trial stage
experienc manag research team
beigen current led mr john oyler season manag team
strong industri experi manag team member serv
charl martineau pm univers toronto pharma compani scienc institut variou function in-depth
understand biotechnolog market well compani oper
figur experienc execut manag beigen
chairman
cfo chief
china
serv ceo director sinc found beigen
founder ceo bioduro integr research cro beij sold
pharmaceut product develop inc attract return
ceo galenea boston biotech start mit fund otsuka
founder presid telephia sold nielsen
co-ceo genta gnta publicli trade oncolog compani grew late
bn revenu
found beigen serv chairman scientif advisori board
found director architect team nation institut biolog
scienc nib beij
biomed scienc professor biomed scienc
univers texa southwestern medic centr
former manag director head biotechnolog equiti research leerink
bloomberg market top us analyst wall street journal best
street
senior biotechnolog analyst ag edward jmp secur associ analyst
prudenti secur cover major special pharmaceut
senior scientist member industri lead structure-bas
drug design team author review paper includ six natur scienc
proceed nation academi scienc
former chief medic offic
vice-president oncolog develop pharmacycl
group medic director genentech
attend physician hematolog servic memori sloan-kett cancer centr
md univers maryland school medicin
year experi pharmaceut industri includ year
lead china oper multi-national compani
countri manag china pfizer/region presid pfizer essenti health
presid manag director wyeth china hong kong
gener manag bayer healthcar china
vice chairman china d-base pharmaceut industri associ committe
phd biochemistri pharmacolog master degre molecular biolog
univers konstanz germani
apart execut manag team also team talent scientist
great knowhow experi lead function beigen
senior team member phd relat field well-known univers
led project pharma compani previous
charl martineau pm univers toronto figur experienc research team beigen
head
head
chemistri
head
act head
chemistri
senior principl scientist group project leader pfizer-la jolla laboratori oncolog
senior scientist tanox acquir genentech
post-doctor assist professor utsw medic centr dalla
phd biochemistri molecular biolog emori univers
ms cell biolog genet wuhan univers
mba univers dalla
year pharmaceut industri experi
former senior director discoveri biolog bioduro built manag
team scientist
group manag oncolog discoveri glaxosmithklin also held role research
investig princip scientist
post-doctor christoph walsh harvard medic school depart biolog
chemistri molecular pharmacolog
phd univers new mexico
bs fudan univers shanghai
year biotech pharmaceut industri experi
former associ director medicin chemistri bioduro manag team
scientist provid integr drug discoveri servic big pharmaceut
research investig genom institut novarti research foundat gnf
senior scientist
post-doctor professor carmelo rizzo vanderbilt univers
phd organ chemistri ms bs lanzhou univers
year pharmaceut experi
former associ director discoveri biolog bioduro manag team
scientist
research investig cardiovascular urolog biolog glaxosmithklin
senior investig high throughput screen
post-doctor professor steve lippard massachusett institut technolog
phd univers new mexico bs tsinghua univers beij
year medicin chemistri pharmaceut experi
led chemistri research team deliv wide prescrib hiv drug efavirenz
raltegravir aid patient
former vice-president head medicin chemistri merck west point laboratori
deliv numer compound across wide rang therapeut area phase ii
clinic program
phd organ chemistri univers california berkeley
bs steven institut technolog
former senior director medicin chemistri bioduro built manag
team scientist
senior research fellow medicin chemistri merck
post-doctor professor martin odonnel indiana university-purdu univers
phd late professor wolfgang oppolz univers geneva switzerland
ms chendu institut organ chemistri
 lanzhou univers
beigen global focus biopharmaceut compani focus discoveri
develop innov molecularli target immuno-oncolog drug
treatment cancer
compani found beij organis focus
develop best-in-class oncolog therapeut beigen develop three major
proprietari programm clinic trial stage
zanubrutinib btk inhibitor investig small molecul inhibitor
bruton tyrosin kinas btk current evalu broad
registr clinic programm global china monotherapi
combin therapi treat variou lymphoma
antibodi immun checkpoint receptor current
evalu broad registr clinic programm global china
monotherapi combin therapi treat variou solid
pamiparib parp inhibitor investig small molecul inhibitor
evalu potenti monotherapi
combin variou solid tumour current pivot clinic trial china
expect enter late-stag develop global
preclin develop proprietari cancer biolog platform also allow
compani develop sever preclinical-stag drug candid consist target
therapi immuno-oncolog agent includ monoclon antibodi
addit raf dimer inhibitor cell surfac protein monoclon antibodi
btk inhibitor non-oncolog indic
commerci oper compani dig find best-in-
class candid also build commercialis capabl
compani build state-of-the-art commercial-scal biolog manufactur
facil guangzhou also compani engag cooper celgen
acquir celgen commerci oper china exclus licens celgen
china cancer commerci portfolio name abraxan revlimid vidaza
figur beigen integr biotech compani broad capabl china global
charl martineau pm univers toronto terminolog abbrevi
figur terminolog abbrevi
newli diagnos multipl myeloma
area curv
gemcitabin cisplatin
compani mention price
